Published Date: 16 Feb 2023
Although there are concerns that the use of Paxlovid increases the risk of COVID-19 returning, the results are clear.
Read Full NewsAn investigative inhaled formulation of the psychedelic mebufotenin is linked to significant improvements in depression symptoms compared to placebo, a phase 2b trial shows.
A biological computer using human neurons learns Doom within 1 week, highlighting rapid adaptive learning and potential advantages over traditional AI systems.
The findings could fill a treatment gap for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who also carry TP53 mutations.
Both drugs increase overall and progression-free survival.
1.
Adjuvant ICIs: A Winner and a Loser in Clear Cell Renal Cell Carcinoma?
2.
The risk of ovarian cancer is not increased by salpingectomy, according to JAMA.
3.
Investigating the Relationship Between GERD and Anxiety/Depression.
4.
Chronic stress and obesity work together to accelerate pancreatic cancer development and growth, study finds
5.
FDA Leaders Explain Their Choice Regarding Cancer Risk Warning in CAR-T Investigation.
1.
Understanding Axitinib: What You Need To Know For Your Treatment Plan
2.
All You Need To Know About Partial Thromboplastin Time (PTT) Test
3.
Unveiling Canine Blood Clots Over Time: A Look at Low-Field MRI's Diagnostic Potential
4.
Screening Strategies in Oncology: A Subspecialty Guide to Early Detection and Better Outcomes
5.
Polyposis Syndrome: Causes, Symptoms, and Treatment Options
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V
3.
Navigating the Complexities of Ph Negative ALL - Part XI
4.
Updates on the First Line Management of ALK+ NSCLC
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation